Siegfried Holding AG (XSWX:SFZN)
CHF 69.65 +1.1 (+1.6%) Market Cap: 3.05 Bil Enterprise Value: 2.95 Bil PE Ratio: 18.15 PB Ratio: 2.70 GF Score: 94/100

Full Year 2025 Siegfried Holding AG Earnings Call Transcript

Feb 20, 2026 / 01:00PM GMT
Release Date Price: CHF82.1 (-8.78%)

Key Points

Positve
  • Siegfried Holding AG (XSWX:SFZN) reported a profitable growth with a core EBITDA margin of 23.5%, showing significant improvement from previous years.
  • The company met its guidance with a 4.3% growth in local currency, demonstrating strong performance despite challenging conditions.
  • The acquisition of Noramco and Extractas is expected to significantly contribute to both top line and bottom line growth in the coming years.
  • Operational excellence initiatives have led to increased efficiency and margin expansion, contributing to the company's strong financial performance.
  • Siegfried Holding AG (XSWX:SFZN) successfully passed four FDA audits, maintaining a strong track record in quality and compliance.
Negative
  • The company faces uncertainty regarding the demand for a large product from one of its customers, impacting growth projections for Drug Substance.
  • Currency headwinds, particularly from the dollar and euro, have posed challenges, affecting the company's financial results.
  • The company experienced a one-time financial impact of CHF7.5 million, which, although positive, is not expected to recur.
  • Despite strong financial performance, the company remains cautious in its guidance for 2026 due to uncertainties with a single customer product.
  • The acquisition of Noramco and Extractas, while promising, depends on the timing of the closing, which could affect the financial outlook for 2026.
Operator

Good afternoon. Nice to see you all again here in Zurich. A warm welcome also to the participants in the webcast. My name is Peter Stierli, I'm the Head of Communications and IR. And with me is, as always, Marcel Imwinkelried, our CEO; and Reto Suter, our CFO.

Marcel will first give us a summary of our numbers, then Reto will talk about the financials a little more detail. And then Marcel will elaborate more on what's ahead next for us in the coming months this year. At the end, we will have a Q&A session. And for those who dialed in through the webcast, you can ask your questions through the audio or video call.

With that, Marcel, I'd like to hand over to you.

Marcel Imwinkelried
Siegfried Holding AG - Chief Operating Officer Drug Products, Member of the Executive Committee

Thank you very much, Peter. I'm really happy. You know why? It's for me the first time that I'm presenting the full year results of Siegfried under my full responsibility for the full year. I'm really proud what we have accomplished as a team, and I'm standing as the

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot